Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2025)
Lineage Cell Therapeutics' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $2.0 million for Q4 2025.
- For Q4 2025, Change in Acquisitions & Divestments fell 33.33% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 71.43%, while the annual FY2025 figure was $2.0 million, 71.43% down from the prior year.
- Change in Acquisitions & Divestments reached $2.0 million in Q4 2025 per LCTX's latest filing, up from -$2.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $24.3 million in Q2 2023 to a low of -$53.3 million in Q4 2023.
- Average Change in Acquisitions & Divestments over 3 years is $919600.0, with a median of $2.5 million recorded in 2024.
- Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 105.63% in 2024, then crashed 11211.11% in 2025.
- A 3-year view of Change in Acquisitions & Divestments shows it stood at -$53.3 million in 2023, then soared by 105.63% to $3.0 million in 2024, then tumbled by 33.33% to $2.0 million in 2025.
- Per Business Quant, the three most recent readings for LCTX's Change in Acquisitions & Divestments are $2.0 million (Q4 2025), -$2.0 million (Q2 2025), and $2.0 million (Q1 2025).